Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Also see the archival list of Science's Compass: Enhanced Perspectives
MEDICINE: Enhanced: A Boost for Translational Neuroscience
Hannelore Ehrenreich
The hematopoietic cytokine EPO not only boosts red blood cell production in the bone marrow (hence its value for treating anemia patients) but also is neuroprotective. In her Perspective, Ehrenreich discusses exciting new research (Leist et al.) in which an EPO derivative is engineered to have neuroprotective activity but not hematopoietic activity. The new drug, called CEPO, should be of value for treating long-term neurological and psychiatric diseases where stimulation of red blood cell production would be a disadvantage.
The author is in the Division of Clinical Neuroscience, Max-Planck Institute for Experimental Medicine, 37075 Goettingen, Germany. E-mail: ehrenreich{at}em.mpg.de
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Marcel Leist, Pietro Ghezzi, Giovanni Grasso, Roberto Bianchi, Pia Villa, Maddalena Fratelli, Costanza Savino, Marina Bianchi, Jacob Nielsen, Jens Gerwien, Pekka Kallunki, Anna Kirstine Larsen, Lone Helboe, Søren Christensen, Lars O. Pedersen, Mette Nielsen, Lars Torup, Thomas Sager, Alessandra Sfacteria, Serhat Erbayraktar, Zubeyde Erbayraktar, Necati Gokmen, Osman Yilmaz, Carla Cerami-Hand, Qiao-wen Xie, Thomas Coleman, Anthony Cerami, and Michael Brines (9 July 2004) Science305 (5681), 239.
[DOI: 10.1126/science.1098313] |Abstract »|Full Text »|PDF »|Supporting Online Material »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Hemoglobin-Independent Organ Protection by EPO in Humans: Amelioration of Cognitive Loss in Chronic Schizophrenia.
H. Ehrenreich, D. Hinze-Selch, S. Stawicki, C. Aust, S. Knolle-Veentjer, S. Wilms, G. Heinz, S. Erdag, H. Jahn, D. Degner, et al. (2007)
J. Am. Soc. Nephrol.
18, 3-6
|Abstract »|Full Text »|PDF »
Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin.
A.-L. Siren, K. Radyushkin, S. Boretius, D. Kammer, C.-C. Riechers, O. Natt, D. Sargin, T. Watanabe, S. Sperling, T. Michaelis, et al. (2006)
Brain
129, 480-489
|Abstract »|Full Text »|PDF »
Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats.
L. Belayev, L. Khoutorova, W. Zhao, A. Vigdorchik, A. Belayev, R. Busto, E. Magal, and M. D. Ginsberg (2005)
Stroke
36, 1065-1070
|Abstract »|Full Text »|PDF »
Reviews of Note.
(2004)
Journal Watch Psychiatry
2004, 6
|Full Text »
Meet CEPO, a Variant of EPO with Great Therapeutic Potential.
(2004)
Journal Watch (General)
2004, 2
|Full Text »
